Description: A Phase 1a/1b Open-label, Dose-Escalation and Expansion Study of TPST-1495 as a Single Agent and in Combination with Pembrolizumab in Subjects with Solid Tumors
Target Patient Population: Uterine, Head and Neck, CRC and tumors with PIK3A in combination with Pembrolizumab
Study Design: Drug is given orally BID.